The Biologics Market continues to evolve as pharmaceutical giants and biotech startups prioritize innovative drug development. The current trend suggests a significant pivot toward monoclonal antibodies and recombinant proteins, which provide superior therapeutic outcomes with reduced side effects. This shift, combined with massive improvements in biotechnology, is fueling a surge in investment...